AAPL336.91+3.89 (+1.17%) ▲|ABBV256.91-2.45 (-0.94%) ▼|ABT104.49+1.43 (+1.39%) ▲|ACN154.06+7.07 (+4.81%) ▲|ADBE237.75+12.64 (+5.62%) ▲|AMAT516.89-19.36 (-3.61%) ▼|AMD494.95-27.00 (-5.17%) ▼|AMGN376.26+0.22 (+0.06%) ▲|AMT166.74+0.07 (+0.04%) ▲|AMZN231.39-0.72 (-0.31%) ▼|AVGO383.22+1.30 (+0.34%) ▲|AXP335.39+9.22 (+2.83%) ▲|BA211.50+1.98 (+0.95%) ▲|BAC62.13+0.08 (+0.13%) ▲|BKNG186.79+9.33 (+5.26%) ▲|BLK1,062.14+6.47 (+0.61%) ▲|BMY62.56+0.47 (+0.76%) ▲|BNY157.77-0.51 (-0.32%) ▼|BRK-B497.18+2.25 (+0.45%) ▲|C133.10+0.91 (+0.69%) ▲|CAT873.28-15.45 (-1.74%) ▼|CL91.98+1.23 (+1.36%) ▲|CMCSA22.80+0.51 (+2.27%) ▲|COF207.05+4.21 (+2.08%) ▲|COP115.58-4.68 (-3.89%) ▼|COST951.58+16.55 (+1.77%) ▲|CRM173.60+9.94 (+6.07%) ▲|CSCO114.57+0.40 (+0.35%) ▲|CVS107.07-0.67 (-0.62%) ▼|CVX190.00-4.79 (-2.46%) ▼|DE625.02-3.14 (-0.50%) ▼|DHR196.50+5.00 (+2.61%) ▲|DIS96.65+1.80 (+1.90%) ▲|DUK128.83-1.69 (-1.29%) ▼|EMR149.30+1.36 (+0.92%) ▲|FDX310.79-4.17 (-1.32%) ▼|GD389.14+2.39 (+0.62%) ▲|GE361.61+7.88 (+2.23%) ▲|GEV996.57-18.18 (-1.79%) ▼|GILD130.52+1.21 (+0.94%) ▲|GM87.04+4.40 (+5.32%) ▲|GOOG326.57+7.48 (+2.34%) ▲|GOOGL326.56+6.82 (+2.13%) ▲|GS1,048.23-13.00 (-1.23%) ▼|HD336.09+3.11 (+0.93%) ▲|HON245.75+2.60 (+1.07%) ▲|IBM216.28+2.09 (+0.98%) ▲|INTC91.67-0.65 (-0.70%) ▼|INTU303.91+7.58 (+2.56%) ▲|ISRG356.83+19.33 (+5.73%) ▲|JNJ265.95+2.55 (+0.97%) ▲|JPM356.20+2.99 (+0.85%) ▲|KO84.07+1.82 (+2.21%) ▲|LIN507.02-5.26 (-1.03%) ▼|LLY1,197.53+1.50 (+0.13%) ▲|LMT580.00-2.60 (-0.45%) ▼|LOW211.55+3.91 (+1.88%) ▲|LRCX291.61-13.60 (-4.46%) ▼|MA551.71+12.05 (+2.23%) ▲|MCD270.67+5.91 (+2.23%) ▲|MDLZ60.67+0.15 (+0.25%) ▲|MDT84.22+1.01 (+1.21%) ▲|META593.87-1.32 (-0.22%) ▼|MMM178.23+5.61 (+3.25%) ▲|MO72.89-0.10 (-0.14%) ▼|MRK130.76-0.31 (-0.24%) ▼|MS214.56+0.08 (+0.04%) ▲|MSFT389.10+7.40 (+1.94%) ▲|MU900.20-20.75 (-2.25%) ▼|NEE88.83-0.95 (-1.06%) ▼|NFLX70.40+0.31 (+0.44%) ▲|NKE42.14+0.44 (+1.06%) ▲|NOW105.56+6.78 (+6.86%) ▲|NVDA196.51-10.33 (-4.99%) ▼|ORCL119.90+4.91 (+4.27%) ▲|PEP139.79+3.15 (+2.31%) ▲|PFE24.67+0.13 (+0.53%) ▲|PG148.63+1.22 (+0.83%) ▲|PLTR131.53+8.61 (+7.00%) ▲|PM195.66+2.66 (+1.38%) ▲|QCOM170.04+3.07 (+1.84%) ▲|RTX218.42+5.63 (+2.65%) ▲|SBUX103.65+0.40 (+0.39%) ▲|SCHW104.18+2.21 (+2.17%) ▲|SO96.48-0.77 (-0.79%) ▼|SPG231.67+1.89 (+0.82%) ▲|T24.42+0.29 (+1.20%) ▲|TMO559.53-8.73 (-1.54%) ▼|TMUS177.21-2.88 (-1.60%) ▼|TSLA309.22-3.81 (-1.22%) ▼|TXN279.41-0.17 (-0.06%) ▼|UBER68.18+2.24 (+3.40%) ▲|UNH417.64-3.10 (-0.74%) ▼|UNP299.30-8.02 (-2.61%) ▼|UPS112.95-1.84 (-1.60%) ▼|USB63.49-0.48 (-0.75%) ▼|V362.53+6.79 (+1.91%) ▲|VZ47.32+0.94 (+2.03%) ▲|WFC87.27+0.96 (+1.11%) ▲|WMT111.74+2.27 (+2.07%) ▲|XOM154.77-2.17 (-1.38%) ▼|AAPL336.91+3.89 (+1.17%) ▲|ABBV256.91-2.45 (-0.94%) ▼|ABT104.49+1.43 (+1.39%) ▲|ACN154.06+7.07 (+4.81%) ▲|ADBE237.75+12.64 (+5.62%) ▲|AMAT516.89-19.36 (-3.61%) ▼|AMD494.95-27.00 (-5.17%) ▼|AMGN376.26+0.22 (+0.06%) ▲|AMT166.74+0.07 (+0.04%) ▲|AMZN231.39-0.72 (-0.31%) ▼|AVGO383.22+1.30 (+0.34%) ▲|AXP335.39+9.22 (+2.83%) ▲|BA211.50+1.98 (+0.95%) ▲|BAC62.13+0.08 (+0.13%) ▲|BKNG186.79+9.33 (+5.26%) ▲|BLK1,062.14+6.47 (+0.61%) ▲|BMY62.56+0.47 (+0.76%) ▲|BNY157.77-0.51 (-0.32%) ▼|BRK-B497.18+2.25 (+0.45%) ▲|C133.10+0.91 (+0.69%) ▲|CAT873.28-15.45 (-1.74%) ▼|CL91.98+1.23 (+1.36%) ▲|CMCSA22.80+0.51 (+2.27%) ▲|COF207.05+4.21 (+2.08%) ▲|COP115.58-4.68 (-3.89%) ▼|COST951.58+16.55 (+1.77%) ▲|CRM173.60+9.94 (+6.07%) ▲|CSCO114.57+0.40 (+0.35%) ▲|CVS107.07-0.67 (-0.62%) ▼|CVX190.00-4.79 (-2.46%) ▼|DE625.02-3.14 (-0.50%) ▼|DHR196.50+5.00 (+2.61%) ▲|DIS96.65+1.80 (+1.90%) ▲|DUK128.83-1.69 (-1.29%) ▼|EMR149.30+1.36 (+0.92%) ▲|FDX310.79-4.17 (-1.32%) ▼|GD389.14+2.39 (+0.62%) ▲|GE361.61+7.88 (+2.23%) ▲|GEV996.57-18.18 (-1.79%) ▼|GILD130.52+1.21 (+0.94%) ▲|GM87.04+4.40 (+5.32%) ▲|GOOG326.57+7.48 (+2.34%) ▲|GOOGL326.56+6.82 (+2.13%) ▲|GS1,048.23-13.00 (-1.23%) ▼|HD336.09+3.11 (+0.93%) ▲|HON245.75+2.60 (+1.07%) ▲|IBM216.28+2.09 (+0.98%) ▲|INTC91.67-0.65 (-0.70%) ▼|INTU303.91+7.58 (+2.56%) ▲|ISRG356.83+19.33 (+5.73%) ▲|JNJ265.95+2.55 (+0.97%) ▲|JPM356.20+2.99 (+0.85%) ▲|KO84.07+1.82 (+2.21%) ▲|LIN507.02-5.26 (-1.03%) ▼|LLY1,197.53+1.50 (+0.13%) ▲|LMT580.00-2.60 (-0.45%) ▼|LOW211.55+3.91 (+1.88%) ▲|LRCX291.61-13.60 (-4.46%) ▼|MA551.71+12.05 (+2.23%) ▲|MCD270.67+5.91 (+2.23%) ▲|MDLZ60.67+0.15 (+0.25%) ▲|MDT84.22+1.01 (+1.21%) ▲|META593.87-1.32 (-0.22%) ▼|MMM178.23+5.61 (+3.25%) ▲|MO72.89-0.10 (-0.14%) ▼|MRK130.76-0.31 (-0.24%) ▼|MS214.56+0.08 (+0.04%) ▲|MSFT389.10+7.40 (+1.94%) ▲|MU900.20-20.75 (-2.25%) ▼|NEE88.83-0.95 (-1.06%) ▼|NFLX70.40+0.31 (+0.44%) ▲|NKE42.14+0.44 (+1.06%) ▲|NOW105.56+6.78 (+6.86%) ▲|NVDA196.51-10.33 (-4.99%) ▼|ORCL119.90+4.91 (+4.27%) ▲|PEP139.79+3.15 (+2.31%) ▲|PFE24.67+0.13 (+0.53%) ▲|PG148.63+1.22 (+0.83%) ▲|PLTR131.53+8.61 (+7.00%) ▲|PM195.66+2.66 (+1.38%) ▲|QCOM170.04+3.07 (+1.84%) ▲|RTX218.42+5.63 (+2.65%) ▲|SBUX103.65+0.40 (+0.39%) ▲|SCHW104.18+2.21 (+2.17%) ▲|SO96.48-0.77 (-0.79%) ▼|SPG231.67+1.89 (+0.82%) ▲|T24.42+0.29 (+1.20%) ▲|TMO559.53-8.73 (-1.54%) ▼|TMUS177.21-2.88 (-1.60%) ▼|TSLA309.22-3.81 (-1.22%) ▼|TXN279.41-0.17 (-0.06%) ▼|UBER68.18+2.24 (+3.40%) ▲|UNH417.64-3.10 (-0.74%) ▼|UNP299.30-8.02 (-2.61%) ▼|UPS112.95-1.84 (-1.60%) ▼|USB63.49-0.48 (-0.75%) ▼|V362.53+6.79 (+1.91%) ▲|VZ47.32+0.94 (+2.03%) ▲|WFC87.27+0.96 (+1.11%) ▲|WMT111.74+2.27 (+2.07%) ▲|XOM154.77-2.17 (-1.38%) ▼|
22.6 C
New York
Tuesday, July 28, 2026

Tag: NO0013524942

newssourceFORcompanyinformationcontent1releasesmarket

Readout from Legacy Ultimovacs DOVACC Phase II Trial Concludes UV1 Programme as Previously Guided

Oslo, 26 June 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today announces that the NSGO-CTU sponsored Phase II DOVACC clinical trial (NCT04742075) investigating the Ultimovacs UV1 cancer vaccine, inherited through the business combination between the two companies in 2025, did not meet the primary endpoint. This concludes the previously communicated wrap-up phase of the UV1 cancer vaccine programme and Zelluna now considers the programme closed.

Resultater fra Ultimovacs’ DOVACC fase II-studie bekrefter avslutningen av UV1-programmet, i tråd med tidligere kommunisert plan

Oslo, 26. juni 2026 – Zelluna (OSE: ZLNA), et selskap som utvikler allogene "off-the-shelf" T-cellereseptor-baserte NK-celler (TCR-NK) for behandling av solide kreftformer, kunngjør i dag at den NSGO-CTU sponsede fase II DOVACC kliniske studie (NCT04742075) som testet Ultimovacs' UV1 kreftvaksine ikke oppnådde sitt primære endepunkt om å forbedre progresjonsfri overlevelse (PFS). UV1 ble overtatt gjennom virksomhetssammenslåingen mellom de to selskapene i 2025. Dette avslutter den tidligere kommuniserte avviklingsfasen av UV1-kreftvaksine-programmet, og Zelluna anser nå programmet som avsluttet.

Zelluna ASA: Disclosure of large shareholding

Reference is made to the stock exchange announcement made by Zelluna ASA (the "Company") on 18 June 2026 regarding the total allocation of 3,143,958 new shares in the Company in a private placement and a retail offering, consisting of 2,972,973 new shares in the private placement and 170,985 new shares in the retail offering through Nordnet Bank AB.

Disclosure of share transfer from Inven2 AS

Issuer: Zelluna ASA
ISIN: NO0013524942
Date of transaction: 25 June 2025

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsNO0013524942

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers